相似文献
1
The pathogenesis of systemic lupus erythematosus-an update.
Curr Opin Immunol. 2012 Dec;24(6):651-7. doi: 10.1016/j.coi.2012.10.004. Epub 2012 Nov 3.
2
Self-DNA at the Epicenter of SLE: Immunogenic Forms, Regulation, and Effects.
Front Immunol. 2019 Jul 10;10:1601. doi: 10.3389/fimmu.2019.01601. eCollection 2019.
3
Aberrant B cell selection and activation in systemic lupus erythematosus.
Int Rev Immunol. 2013 Aug;32(4):445-70. doi: 10.3109/08830185.2013.786712. Epub 2013 Jun 14.
4
Emerging and critical issues in the pathogenesis of lupus.
Autoimmun Rev. 2013 Feb;12(4):523-36. doi: 10.1016/j.autrev.2012.09.003. Epub 2012 Sep 18.
5
Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus.
Inflamm Res. 2022 Jun;71(5-6):537-554. doi: 10.1007/s00011-022-01554-6. Epub 2022 Mar 17.
6
Immunopathogenesis of systemic lupus erythematosus: An update.
Autoimmun Rev. 2024 Oct;23(10):103648. doi: 10.1016/j.autrev.2024.103648. Epub 2024 Sep 27.
7
B cells biology in systemic lupus erythematosus-from bench to bedside.
Sci China Life Sci. 2015 Nov;58(11):1111-25. doi: 10.1007/s11427-015-4953-x. Epub 2015 Nov 13.
8
B cell biology: implications for treatment of systemic lupus erythematosus.
Lupus. 2013 Apr;22(4):342-9. doi: 10.1177/0961203312471576.
9
Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective.
Trends Mol Med. 2017 Jul;23(7):615-635. doi: 10.1016/j.molmed.2017.05.006. Epub 2017 Jun 13.
10
Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus.
Autoimmunity. 2017 Jun;50(4):257-268. doi: 10.1080/08916934.2017.1300884. Epub 2017 Mar 16.
引用本文的文献
1
Autoantibodies in Systemic Lupus Erythematosus: Diagnostic and Pathogenic Insights.
J Clin Med. 2025 Aug 12;14(16):5714. doi: 10.3390/jcm14165714.
2
Inhibition of VEGFR-3 by SAR131675 decreases renal inflammation and lymphangiogenesis in the murine lupus nephritis model.
Cell Death Discov. 2025 Jul 12;11(1):320. doi: 10.1038/s41420-025-02624-4.
3
Advancing understanding of autoimmune diseases and lung cancer: trends, themes, and future directions.
Discov Oncol. 2025 Jul 7;16(1):1275. doi: 10.1007/s12672-025-03145-3.
4
Identification of Differentially Expressed Genes in Spinal Cord Injury.
Genes (Basel). 2025 Apr 28;16(5):514. doi: 10.3390/genes16050514.
5
IL-7 in autoimmune diseases: mechanisms and therapeutic potential.
Front Immunol. 2025 Apr 17;16:1545760. doi: 10.3389/fimmu.2025.1545760. eCollection 2025.
6
New Diagnosis of Lupus Nephritis in the Third Trimester-A Case Report.
Nephrology (Carlton). 2025 May;30(5):e70037. doi: 10.1111/nep.70037.
7
Maternal Immune Activation: Implications for Congenital Heart Defects.
Clin Rev Allergy Immunol. 2025 Apr 2;68(1):36. doi: 10.1007/s12016-025-09049-y.
8
Predictors of Mortality in Acute Myocardial Infarction Patients With Systemic Lupus Erythematosus.
Cureus. 2025 Feb 24;17(2):e79578. doi: 10.7759/cureus.79578. eCollection 2025 Feb.
9
Role of Microbiota-Derived Hydrogen Sulfide (HS) in Modulating the Gut-Brain Axis: Implications for Alzheimer's and Parkinson's Disease Pathogenesis.
Biomedicines. 2024 Nov 23;12(12):2670. doi: 10.3390/biomedicines12122670.
10
Mechanisms governing bystander activation of T cells.
Front Immunol. 2024 Nov 27;15:1465889. doi: 10.3389/fimmu.2024.1465889. eCollection 2024.
本文引用的文献
1
Extrafollicular B cell activation by marginal zone dendritic cells drives T cell-dependent antibody responses.
J Exp Med. 2012 Sep 24;209(10):1825-40. doi: 10.1084/jem.20120774. Epub 2012 Sep 10.
2
The genetics of type I interferon in systemic lupus erythematosus.
Curr Opin Immunol. 2012 Oct;24(5):530-7. doi: 10.1016/j.coi.2012.07.008. Epub 2012 Aug 10.
3
Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome.
Curr Opin Rheumatol. 2012 Sep;24(5):451-6. doi: 10.1097/BOR.0b013e32835707e4.
4
Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus.
J Rheumatol. 2012 Sep;39(9):1819-28. doi: 10.3899/jrheum.120468. Epub 2012 Aug 1.
5
Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.
Arthritis Rheum. 2012 Nov;64(11):3666-76. doi: 10.1002/art.34632.
6
Treatment of systemic lupus erythematosus: new advances in targeted therapy.
Ann N Y Acad Sci. 2012 Jan;1247:138-52. doi: 10.1111/j.1749-6632.2011.06263.x. Epub 2012 Jan 11.
7
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
Arthritis Rheum. 2012 Apr;64(4):1215-26. doi: 10.1002/art.34359. Epub 2012 Jan 9.
8
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613.
9
IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus.
Ann Rheum Dis. 2012 Mar;71(3):463-8. doi: 10.1136/annrheumdis-2011-200463. Epub 2011 Nov 16.
10
Neutrophils in the pathogenesis and manifestations of SLE.
Nat Rev Rheumatol. 2011 Sep 27;7(12):691-9. doi: 10.1038/nrrheum.2011.132.
Zotero 插件